US › Healthcare

Entera Bio Ltd (ENTX)

US · Healthcare · Biotechnology

$3.14+5.02%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.3M

EPS

$-0.14

EPS estimate

$-0.08

EPS came in at -0.14 against a street estimate of -0.08 — a miss of 75.0%.

Key statistics

Market cap

$520.0M

Forward P/E

0.0

P/B

73.25

Book value

$0.15

EPS (TTM)

$-0.36

52-week high

$4.20

52-week low

$0.91

50-day MA

$2.88

200-day MA

$1.93

Beta

1.46

Analyst view

Analysts rate Entera Bio Ltd a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $9.75.

Shareholding

Insiders

5.42%

Institutions

39.18%

Largest institutional holders

Fund	Stake
Knoll Capital Management LP	3.38%
Bvf Inc	1.40%
Siren, L.L.C.	0.42%
Renaissance Technologies Corp	0.21%
Parkman Healthcare Partners LLC	0.16%
PNC Financial Services Group Inc	0.16%
Seven Fleet Capital Management LP	0.11%
HighTower Advisors, LLC	0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Entera Bio Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.